Amylyx

@AmylyxPharma

Dedicated to Finding and Developing New Treatments for ALS, Alzheimer's, and all Neurodegenerative Diseases

Vrijeme pridruživanja: veljača 2019.

Tweetovi

Blokirali ste korisnika/cu @AmylyxPharma

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AmylyxPharma

  1. 4. velj

    Welcome to the team as Amylyx' CFO, Jeff Trigilio! Jeff's leadership and financial acumen will be essential as we continue our mission to develop new treatments for and 's disease and bring them to patients and families as rapidly as we can.

    Poništi
  2. proslijedio/la je Tweet
    16. sij

    "I believe that the problems we face are our opportunity and define our human purpose." Former player and ALS champion accepted the Congressional Gold Medal yesterday and delivered a powerful message we can all get behind 👏

    Poništi
  3. 1. sij
    Poništi
  4. 18. pro 2019.

    We are thrilled to celebrate the news of the CENTAUR study topline results with the community. Thank you for your tremendous support and encouragement. Stay tuned for more updates in 2020!

    Poništi
  5. 17. pro 2019.

    On the morning of the CENTAUR study topline results announcement, advocates from took over Times Square to raise awareness of the need to develop new treatments for and other neurodegenerative diseases. Today’s events are a reminder that together, we can

    Poništi
  6. 17. pro 2019.

    Thank you for helping us share this exciting news. People with have no time to lose, so we're moving as quickly as possible to submit detailed results from the CENTAUR study for peer-reviewed publication and presentation at a future medical congress.

    Poništi
  7. proslijedio/la je Tweet

    If its promising data hold up when released in full, the ALS drug from Amylyx Pharmaceuticals could lead a wave of new treatments for the progressive, fatal disease

    Poništi
  8. proslijedio/la je Tweet

    Amylyx drug helps slow ALS progression in mid-stage study

    Poništi
  9. 17. pro 2019.

    We're proud to announce the topline results today. Thank you to the participants and their families, clinics and groups who supported this trial. We're encouraged and incredibly eager to press ahead in the fight for people with

    Poništi
  10. 13. pro 2019.

    "We’ve taken a closer look at how far we’ve come with an exciting trial underway, all of which is possible thanks to those fighting relentlessly alongside us," shared Dr. Patrick Yeramian via 's Alzheimer's Matters Blog. Read more here:

    Poništi
  11. 13. pro 2019.

    Welcome to the team, Deb. We're looking forward to continuing to build a culture geared toward improving the lives of those suffering from disease.

    Poništi
  12. 9. pro 2019.

    Our deepest condolences to the Frates family, we've lost a true hero today. But Pete’s spirit and ability to bring people together will continue to inspire and drive the fight for new treatments.

    Poništi
  13. 11. stu 2019.

    Today and every day let's celebrate and honor those who have served our nation in the armed forces. Thank you for your service and courage.

    Poništi
  14. 1. stu 2019.

    Earlier this month, in completed its last-patient/ last-visit. Amylyx is currently working feverishly to complete analysis and share results. Read more, as told by , here

    Poništi
  15. 30. lis 2019.

    In a recent interview with , cofounder and PI discussed Amylyx' mission to do right by patients if this trial is a success and the impact of a partnership between industry and academia. Read more:

    Poništi
  16. 18. lis 2019.

    Congratulations to Principal Investigator on this incredible recognition for all of your efforts in the community.

    Poništi
  17. 7. lis 2019.

    The last participant has completed the planned 24 weeks of study treatment! We’re working quickly to share data with the Community in the next few months

    Poništi
  18. 5. lis 2019.

    We’re thrilled to announce the last participant has completed the planned 24 weeks of study treatment. "Thank you to the participants and site study teams who have made this work possible,” said Principle Investigator, .

    Poništi
  19. 3. lis 2019.

    Today at , Principal Investigator of , , presented the novel features and design of the clinical trial. We’re proud to share nearly 90% of participants have elected to continue into the open label extension

    Poništi
  20. 3. lis 2019.

    Thank you for all of the wonderful things you do for pALS and the community - you inspire us every day

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·